Myotonic Disorders clinical trials at University of California Health
2 in progress, 0 open to eligible people
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Sorry, in progress, not accepting new patients
AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients
at UCLA
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Sorry, accepting new patients by invitation only
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
at UCLA
Our lead scientists for Myotonic Disorders research studies include Payam Soltanzadeh, MD.
Last updated: